David Rafei‐Shamsabadi

1.2k total citations
25 papers, 356 citations indexed

About

David Rafei‐Shamsabadi is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, David Rafei‐Shamsabadi has authored 25 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in David Rafei‐Shamsabadi's work include Cancer Immunotherapy and Biomarkers (7 papers), Food Allergy and Anaphylaxis Research (6 papers) and Allergic Rhinitis and Sensitization (5 papers). David Rafei‐Shamsabadi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Food Allergy and Anaphylaxis Research (6 papers) and Allergic Rhinitis and Sensitization (5 papers). David Rafei‐Shamsabadi collaborates with scholars based in Germany, Switzerland and Denmark. David Rafei‐Shamsabadi's co-authors include Frank Meiß, Sabine Müller, Edzard Spillner, Thilo Jakob, Dagmar von Bubnoff, Thilo Jakob, Yakup Tanriver, Timotheus Y.F. Halim, Justus Duyster and Thilo Jakob and has published in prestigious journals such as Frontiers in Immunology, Journal of Investigative Dermatology and European Journal of Cancer.

In The Last Decade

David Rafei‐Shamsabadi

24 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Rafei‐Shamsabadi Germany 10 122 105 88 78 58 25 356
Kimio Fujii Japan 10 63 0.5× 73 0.7× 128 1.5× 68 0.9× 57 1.0× 25 348
Fanny Coudane France 8 45 0.4× 71 0.7× 150 1.7× 47 0.6× 33 0.6× 9 318
Shengxian Shen China 10 47 0.4× 222 2.1× 111 1.3× 12 0.2× 98 1.7× 22 437
Patrik Wernhoff Sweden 14 136 1.1× 138 1.3× 157 1.8× 60 0.8× 5 0.1× 26 452
Kangling Xu United States 3 130 1.1× 174 1.7× 81 0.9× 44 0.6× 60 1.0× 7 309
Sohshi Morimura Japan 11 87 0.7× 175 1.7× 67 0.8× 32 0.4× 136 2.3× 19 352
Hui Cheng China 13 55 0.5× 256 2.4× 83 0.9× 33 0.4× 137 2.4× 32 411
Qing-Xia Fan China 13 106 0.9× 21 0.2× 187 2.1× 25 0.3× 25 0.4× 39 403
Irina Lerman United States 8 81 0.7× 158 1.5× 84 1.0× 42 0.5× 10 0.2× 13 316
Dilip Kumar Singapore 8 70 0.6× 187 1.8× 131 1.5× 32 0.4× 6 0.1× 15 351

Countries citing papers authored by David Rafei‐Shamsabadi

Since Specialization
Citations

This map shows the geographic impact of David Rafei‐Shamsabadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Rafei‐Shamsabadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Rafei‐Shamsabadi more than expected).

Fields of papers citing papers by David Rafei‐Shamsabadi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Rafei‐Shamsabadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Rafei‐Shamsabadi. The network helps show where David Rafei‐Shamsabadi may publish in the future.

Co-authorship network of co-authors of David Rafei‐Shamsabadi

This figure shows the co-authorship network connecting the top 25 collaborators of David Rafei‐Shamsabadi. A scholar is included among the top collaborators of David Rafei‐Shamsabadi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Rafei‐Shamsabadi. David Rafei‐Shamsabadi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rafei‐Shamsabadi, David, Sisi Lu, Daniele Castiglia, et al.. (2024). Epidermolysis-Bullosa-Associated Squamous Cell Carcinomas Support an Immunosuppressive Tumor Microenvironment: Prospects for Immunotherapy. Cancers. 16(2). 471–471. 3 indexed citations
2.
Kähler, Katharina C., Ralf Gutzmer, Elisabeth Livingstone, et al.. (2024). Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective. Journal of Cancer Research and Clinical Oncology. 150(5). 252–252.
3.
Kähler, Katharina C., D. Nashan, David Rafei‐Shamsabadi, et al.. (2023). Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial). Journal of Cancer Research and Clinical Oncology. 149(13). 11705–11718. 2 indexed citations
4.
Technau‐Hafsi, Kristin, et al.. (2023). Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa. Acta Dermato Venereologica. 103. adv4870–adv4870. 6 indexed citations
5.
Hudemann, Christoph, Robert Pollmann, Anna Zakrzewicz, et al.. (2022). IgG against the Membrane-Proximal Portion of the Desmoglein 3 Ectodomain Induces Loss of Keratinocyte Adhesion, a Hallmark in Pemphigus Vulgaris. Journal of Investigative Dermatology. 143(2). 254–263.e3. 8 indexed citations
6.
Zhang, Zhen, David Rafei‐Shamsabadi, Nico Buettner, et al.. (2022). Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity. Journal of Translational Medicine. 20(1). 582–582. 3 indexed citations
7.
Salzmann, Martin, Carmen Loquai, David Rafei‐Shamsabadi, et al.. (2022). MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study. European Journal of Cancer. 166. 24–32. 11 indexed citations
8.
Schauer, Franziska, David Rafei‐Shamsabadi, Yosuke Mai, et al.. (2022). Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid—A Retrospective, Monocentric Study. Frontiers in Immunology. 13. 953546–953546. 8 indexed citations
9.
10.
Rafei‐Shamsabadi, David, et al.. (2021). Case Report: Blurred Vision and Eruptive Nevi - Bilateral Diffuse Uveal Melanocytic Proliferation With Mucocutaneous Involvement in a Lung Cancer Patient. Frontiers in Oncology. 11. 658407–658407. 7 indexed citations
11.
Rawluk, Justyna, Annette Schmitt‐Graeff, Federico Simonetta, et al.. (2020). MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors. JCI Insight. 5(6). 64 indexed citations
12.
Thriene, Kerstin, Christine Gretzmeier, Tobias Kühl, et al.. (2020). Proteomic Profiling of Fibroblasts Isolated from Chronic Wounds Identifies Disease-Relevant Signaling Pathways. Journal of Investigative Dermatology. 140(11). 2280–2290.e4. 22 indexed citations
13.
Lu, Saideng, Moritz Hess, Daniele Castiglia, et al.. (2019). 302 Molecular and mutational signatures of squamous cell carcinomas in epidermolysis bullosa. Journal of Investigative Dermatology. 139(9). S266–S266. 1 indexed citations
14.
15.
Tietze, Julia K., Andrea Forschner, Carmen Loquai, et al.. (2018). The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study. Oncotarget. 9(76). 34336–34346. 24 indexed citations
16.
Rafei‐Shamsabadi, David, Stefanie Kunz, Stefan F. Martin, et al.. (2018). Lack of Type 2 Innate Lymphoid Cells Promotes a Type I-Driven Enhanced Immune Response in Contact Hypersensitivity. Journal of Investigative Dermatology. 138(9). 1962–1972. 28 indexed citations
17.
Jakob, Thilo, David Rafei‐Shamsabadi, Edzard Spillner, & Sabine Müller. (2017). Diagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnostics. Allergo Journal International. 26(3). 93–105. 45 indexed citations
18.
Müller, Sabine, et al.. (2015). Bullous Delayed Pressure Urticaria Responding to Omalizumab. Acta Dermato Venereologica. 96(3). 416–417. 7 indexed citations
19.
Müller, Sabine, David Rafei‐Shamsabadi, & Thilo Jakob. (2014). Problemfälle der In-vitro-Diagnostik bei Hymenopterengiftallergie. Der Hautarzt. 65(9). 780–790. 6 indexed citations
20.
Vaerenbergh, Matthias Van, Lina De Smet, David Rafei‐Shamsabadi, et al.. (2014). IgE recognition of chimeric isoforms of the honeybee (Apis mellifera) venom allergen Api m 10 evaluated by protein array technology. Molecular Immunology. 63(2). 449–455. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kimio Fujii Breakdown of academic impact, for papers by Fanny Coudane Breakdown of academic impact, for papers by Shengxian Shen Breakdown of academic impact, for papers by Patrik Wernhoff Breakdown of academic impact, for papers by Kangling Xu Breakdown of academic impact, for papers by Sohshi Morimura Breakdown of academic impact, for papers by Hui Cheng Breakdown of academic impact, for papers by Qing-Xia Fan Breakdown of academic impact, for papers by Irina Lerman Breakdown of academic impact, for papers by Dilip Kumar
Rankless by CCL
2026